cerebral dopamine neurotrophic factor

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
cerebral dopamine neurotrophic factor (Human)

GtoPdb Ligand ID: 13048

Synonyms: arginine-rich, mutated in early stage tumors-like 1 | ARMETL1

Compound class: Endogenous peptide in human, mouse or rat

Comment: CDNF is a dopamine neuron neurotropic factor [5]. It provides cytoprotective effects in neurodegenerative disease models by reducing the activating effect of endoplasmic reticulum stress on the unfolded protein response (UPR) pathway [4,7]. Specifically, CDNF has been shown to protect dopamine neurons and improve motor function in animal Parkinson's disease models [1-2,5-6,8]. However therapeutic use of proteins like CDNF is invasive (intracranial administration) and requires clinical expertise.

Species: Human

References
1. Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B et al.. (2012) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant, 21 (6): 1213-23. [PMID:21943517]
2. Er S, Airavaara M. (2023) Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease. Biochem Soc Trans, 51 (1): 245-257. [PMID:36794783]
3. Huttunen HJ, Booms S, Sjögren M, Kerstens V, Johansson J, Holmnäs R, Koskinen J, Kulesskaya N, Fazio P, Woolley M et al.. (2023) Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial. Mov Disord, 38 (7): 1209-1222. [PMID:37212361]
4. Lindholm P, Saarma M. (2022) Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol Psychiatry, 27 (3): 1310-1321. [PMID:34907395]
5. Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T et al.. (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature, 448 (7149): 73-7. [PMID:17611540]
6. Pakarinen E, Lindholm P. (2023) CDNF and MANF in the brain dopamine system and their potential as treatment for Parkinson's disease. Front Psychiatry, 14: 1188697. [PMID:37555005]
7. van Ziel AM, Scheper W. (2020) The UPR in Neurodegenerative Disease: Not Just an Inside Job. Biomolecules, 10 (8): 1090. [PMID:32707908]
8. Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK. (2011) Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol, 228 (1): 99-108. [PMID:21185834]

References

1. Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B et al.. (2012)
CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.
Cell Transplant, 21 (6): 1213-23. [PMID:21943517]

2. Er S, Airavaara M. (2023)
Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
Biochem Soc Trans, 51 (1): 245-257. [PMID:36794783]

3. Huttunen HJ, Booms S, Sjögren M, Kerstens V, Johansson J, Holmnäs R, Koskinen J, Kulesskaya N, Fazio P, Woolley M et al.. (2023)
Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
Mov Disord, 38 (7): 1209-1222. [PMID:37212361]

4. Lindholm P, Saarma M. (2022)
Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism.
Mol Psychiatry, 27 (3): 1310-1321. [PMID:34907395]

5. Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T et al.. (2007)
Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
Nature, 448 (7149): 73-7. [PMID:17611540]

6. Pakarinen E, Lindholm P. (2023)
CDNF and MANF in the brain dopamine system and their potential as treatment for Parkinson's disease.
Front Psychiatry, 14: 1188697. [PMID:37555005]

7. van Ziel AM, Scheper W. (2020)
The UPR in Neurodegenerative Disease: Not Just an Inside Job.
Biomolecules, 10 (8): 1090. [PMID:32707908]

8. Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK. (2011)
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
Exp Neurol, 228 (1): 99-108. [PMID:21185834]